La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Pliant Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Pliant Therapeutics sono diminuiti a un tasso medio annuo di -45.9%, mentre il settore Pharmaceuticals ha visto gli utili diminuire a un tasso medio annuo di 0.2%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 56.3%.

Informazioni chiave

-45.9%

Tasso di crescita degli utili

-39.9%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	-56.3%
Rendimento del capitale proprio	-47.2%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21

Ripartizione dei ricavi e delle spese

Come Pliant Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:PLRX Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	0	-185	59	148
31 Mar 24	0	-171	59	136
31 Dec 23	2	-161	58	128
30 Sep 23	4	-155	58	120
30 Jun 23	5	-144	52	112
31 Mar 23	10	-133	46	105
31 Dec 22	10	-123	40	97
30 Sep 22	10	-113	34	91
30 Jun 22	10	-109	32	87
31 Mar 22	7	-103	30	80
31 Dec 21	8	-97	28	78
30 Sep 21	10	-92	25	77
30 Jun 21	13	-81	22	72
31 Mar 21	15	-75	20	71
31 Dec 20	42	-42	17	66
30 Sep 20	94	18	15	60
30 Jun 20	90	19	13	54
31 Mar 20	86	20	12	50
31 Dec 19	57	-7	11	47
31 Mar 19	0	-43	8	31
31 Dec 18	0	-35	7	24

Guadagni di qualità: PLRX al momento non è redditizia.

Margine di profitto in crescita: PLRX al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: PLRX non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 45.9% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di PLRX nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: PLRX non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 13% ).

Rendimento del capitale proprio

ROE elevato: PLRX ha un Return on Equity negativo ( -47.22% ), in quanto al momento non è redditizio.

Pliant Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2023 earnings released: US$0.69 loss per share (vs US$0.65 loss in 3Q 2022)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 69%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.1% to US$42.67

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$44.08

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings released: US$0.69 loss per share (vs US$0.65 loss in 3Q 2022)

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Consensus revenue estimates fall by 32%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Business Officer notifies of intention to sell stock

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 123%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel & Corporate Secretary notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

President notifies of intention to sell stock

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Price target increased by 17% to US$49.09

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

President notifies of intention to sell stock

Insufficient new directors

General Counsel & Corporate Secretary notifies of intention to sell stock

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$256k worth of stock

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics: Wait For A Better Price To Get In

Consensus revenue estimates increase by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant's PLN-74809 gets FDA fast track status for liver disease

Price target increased to US$43.71

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant: Major Catalyst Expected Beginning Of 2023

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

Price target decreased to US$39.67

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate